IMPALA-2: Choice of DLco as a Primary Endpoint in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Home / IMPALA-2: Choice of DLco as a Primary Endpoint in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

See poster

We use cookies to give you the best online experience. By accepting, you agree to the use of cookies in accordance with our cookie policy.

I Accept I Decline